By Counterforce Health Team in Qinlock (ripretinib) —

How to Get Qinlock (Ripretinib) Covered by Cigna in Washington: Complete Prior Authorization and Appeals Guide

Quick Answer: Getting Qinlock Covered by Cigna in Washington

Qinlock (ripretinib) requires prior authorization from Cigna for fourth-line GIST treatment. You'll need documented failure of three prior kinase inhibitors (imatinib, sunitinib, regorafenib), pathology confirming GIST diagnosis, and recent imaging showing disease progression. Submit through your oncologist to Cigna's provider portal with complete medical records. If denied, Washington residents have strong appeal rights including external review through an Independent Review Organization (IRO). First step: Ask your oncologist to start the prior authorization process today.

Table of Contents

Prior Authorization Requirements

Cigna requires prior authorization for Qinlock (ripretinib) because it's a high-cost specialty oncology drug approved for fourth-line GIST treatment. Here's what your oncologist must submit:

Core Documentation Requirements:

  • GIST diagnosis confirmation with pathology report and immunohistochemistry (KIT/CD117, DOG1)
  • Prior therapy history documenting failure or intolerance of three kinase inhibitors:
    • Imatinib (first-line)
    • Sunitinib (second-line)
    • Regorafenib (third-line)
  • Disease progression evidence with imaging studies (CT scans within 3 months)
  • Performance status (ECOG 0-2 typically required)
  • Baseline labs and cardiac function (CBC, metabolic panel, LVEF, blood pressure)
Note: Qinlock must be dispensed through Accredo specialty pharmacy, Cigna's required specialty pharmacy network.

Step-by-Step: Fastest Path to Approval

  1. Gather Complete Medical Records (Patient + Clinic)
    • Insurance card and policy details
    • Pathology reports confirming GIST
    • Treatment history with dates and outcomes for all three prior TKIs
    • Recent imaging studies showing progression
  2. Oncologist Submits Prior Authorization (Clinic)
    • Submit via Cigna provider portal
    • Include medical necessity letter citing FDA approval and NCCN guidelines
    • Timeline: 1-3 business days for decision
  3. Monitor Authorization Status (Patient)
    • Track through Cigna member portal or call customer service
    • Ensure Accredo receives approved authorization for dispensing
  4. If Denied: File Internal Appeal (Patient + Clinic)
    • Submit within 180 days of denial
    • Include additional clinical documentation and peer-reviewed studies
  5. If Still Denied: Request External Review (Patient)
    • File with Washington's Office of Insurance Commissioner
    • Independent Review Organization makes binding decision

Common Denial Reasons & How to Fix Them

Denial Reason How to Overturn
Insufficient prior therapy documentation Submit detailed treatment records with dates, doses, and progression notes for imatinib, sunitinib, and regorafenib
"Not medically necessary" Include NCCN guideline citation and FDA label indication for fourth-line GIST treatment
Missing disease progression evidence Provide recent imaging (CT scans) with radiologist reports documenting tumor growth
Step therapy not met Document specific reasons each prior TKI failed (progression, intolerance, contraindications)
Quantity limits exceeded Justify dosing with FDA label and any dose modifications due to side effects

Appeals Process in Washington

Washington state provides strong consumer protections for insurance denials through RCW 48.43.535.

Internal Appeals (Required First Step)

  • Timeline: 180 days from denial to file
  • Process: Submit to Cigna with additional clinical evidence
  • Decision: Cigna must respond within reasonable timeframe

External Review (Independent Review Organization)

  • Eligibility: After internal appeal denial
  • Timeline: 180 days from final internal denial to request
  • Process: Washington Office of Insurance Commissioner assigns certified IRO
  • Decision: Standard review within 30 days; expedited within 72 hours for urgent cases
  • Outcome: Binding on Cigna if approved
Important: External review decisions are binding on Cigna. If the IRO approves Qinlock, Cigna must provide coverage.

Expedited Review

If waiting would seriously jeopardize your health, request expedited review:

  • Timeline: 72 hours for IRO decision
  • Requirements: Medical documentation showing urgent need
  • Process: Same as standard review but accelerated

Medical Necessity Documentation

Your oncologist's medical necessity letter should include these key elements:

Essential Components:

  1. Diagnosis: Advanced GIST with specific ICD-10 codes (C15-C20 series for digestive organ malignancies)
  2. Prior therapies: Detailed history of imatinib, sunitinib, and regorafenib with outcomes
  3. Disease progression: Recent imaging demonstrating tumor growth
  4. Treatment rationale: FDA approval for fourth-line GIST treatment
  5. Guideline support: NCCN or other recognized oncology guidelines
  6. Monitoring plan: Safety monitoring for cardiac function and other side effects

Sample Language: "Patient has advanced GIST with documented progression after sequential treatment with imatinib, sunitinib, and regorafenib. Qinlock (ripretinib) is FDA-approved for this fourth-line indication and represents the appropriate next step per NCCN guidelines."

Costs and Financial Assistance

Typical Costs:

  • Cash price: ~$43,000-$48,000 per month
  • With insurance: Varies by plan design and specialty pharmacy copays

Financial Assistance Options:

  • Deciphera Patient Support Program: Copay assistance and financial counseling
  • Cancer support foundations: Various organizations provide grants for specialty medications
  • State programs: Washington Apple Health (Medicaid) may cover for eligible patients
Tip: Contact Accredo specialty pharmacy for assistance navigating financial support programs.

When to Contact Washington's Insurance Commissioner

Contact the Washington Office of Insurance Commissioner at 1-800-562-6900 if:

  • Cigna delays prior authorization beyond reasonable timeframes
  • You need help understanding your appeal rights
  • You believe Cigna violated Washington insurance laws
  • You need assistance with the external review process

The OIC provides free consumer advocacy and can help navigate complex insurance issues.

Frequently Asked Questions

How long does Cigna prior authorization take in Washington? Typically 1-3 business days for complete submissions. Washington doesn't specify faster timelines than federal requirements, but incomplete submissions cause delays.

What if Qinlock isn't on Cigna's formulary? Request a formulary exception with medical necessity documentation. Your oncologist must demonstrate why formulary alternatives aren't appropriate.

Can I get expedited review if my condition is urgent? Yes. If waiting would seriously jeopardize your health, request expedited review from both Cigna (24-72 hours) and Washington's IRO process (72 hours).

Does step therapy apply if I failed prior TKIs outside Washington? Yes, as long as you have medical records documenting the treatment history and outcomes. The location of prior treatment doesn't matter.

What happens if the external review approves Qinlock? Cigna must provide coverage. The IRO decision is binding, and failure to comply can result in penalties up to $50,000.

How much does the appeals process cost? Nothing. Washington law prohibits charging patients for internal appeals or external review. You cannot be charged fees for exercising your appeal rights.

Getting specialty cancer medications approved can feel overwhelming, but Washington residents have strong legal protections and support systems. If you're struggling with a Cigna denial for Qinlock, consider working with patient advocacy organizations that specialize in insurance appeals.

Counterforce Health helps patients, clinicians, and specialty pharmacies turn insurance denials into targeted, evidence-backed appeals. The platform analyzes denial letters and plan policies to identify the specific denial basis, then drafts point-by-point rebuttals using the right clinical evidence and payer-specific requirements. For complex cases like Qinlock appeals, having expert support can significantly improve approval chances while reducing the administrative burden on busy oncology practices.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan documents for specific coverage details. Insurance policies and state regulations may change; verify current requirements with official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.